clinical trial · NCT03778424
An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
Lennox Gastaut SyndromeRufinamide
brief summary
This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
started
—
primary completion
—
completion
—
last updated
Jul 17, 2025
official title
An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol